Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Narrative)

v3.21.2
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Finite-Lived Intangible Assets [Line Items]        
Amortization expense $ 195,700 $ 198,832 $ 593,365 $ 596,496
Future amortization expense 790,000   790,000  
Future amortization expense, annual periods thereafter 788,000   788,000  
License Rights [Member] | CoNCERT Pharmaceuticals, Inc [Member]        
Finite-Lived Intangible Assets [Line Items]        
Purchase price 8,000,000   8,000,000  
Transaction cost 1,782   1,782  
Recognition of deferred tax liability 3,037,147   3,037,147  
Intangible asset, tax basis $ 1,782   $ 1,782